[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Corewell Health East\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":248},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,74,97,119,132,151,174,198,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054236","sacral-neuromodulation-for-chronic-pelvic-pain-100054236",false,"NCT06150599","Sacral Neuromodulation for Chronic Pelvic Pain","Sacral Neuromodulation for the Treatment of Chronic Pelvic Pain","SNM_CPP","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Female, aged 22-70\n4. Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient)\n5. Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations)\n6. No changes to current regimen of medications for their pelvic pain for \\> 4 weeks prior to screening\n7. For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation\n8. Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)\n\nExclusion Criteria:\n\n1. History of any active pelvic cancer\n2. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints\n3. Concurrent pain management strategies within the past 3 months that may interfere or mask study intervention (e.g. pelvic floor physical therapy, shockwave therapy, trigger point injections, bladder instillations)\n4. Any psychiatric or personality disorder at the discretion of the study physician. This does not include depression or generalized anxiety disorders that are stable.\n5. Current symptomatic urinary tract infection (UTI) or more than 6 UTIs in past year\n6. Severe or uncontrolled diabetes (A1C \\> 7, documented in the last 3 months) or diabetes with peripheral nerve involvement\n7. Interstitial cystitis diagnosis with Hunner's lesions as this is a severe inflammatory bladder condition that can only be treated with eradication of the lesions or a cystectomy. SNM would be be expected to help for IC with Hunner's lesions\n8. Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial\n9. Subject with documented history of allergy to titanium, zirconia, polyurethane, epoxy, or silicone\n10. Implantation of spinal cord stimulator and\u002For drug delivery pumps, whether turned on or off\n11. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception\n12. Current treatment for active malignancy (skin cancers excluded)\n13. Patients with spinal pathology that could confound study results. This may include participants with cauda equina syndrome, spinal stenosis, neurogenic claudication, lumbar radiculopathy, patients with primary complaints of leg pain with numbness and or weakness, patients with a primary pain compliant that is vascular in origin, clinical evidence of progressive neurologic pathology, mechanical instability or other spinal pathology that requires surgical intervention, spine or visceral pain secondary to neoplasm, visceral pain in the upper abdomen rather than the pelvis, current diagnosis of fibromyalgia participants with significant cognitive impairment, participants with a condition currently requiring or likely to require use of diathermy or MRI or history of any other condition that in the opinion of the investigator could put the participant at risk or interfere with study results interpretation. (screening patient).\n14. Participants involved in ongoing litigation and or injury claims or workers compensation claims.\n15. Participation in a current clinical trial or within the preceding 30 days\n\nNote- to preserve the scientific integrity of the study some criteria have been omitted from this posting. All eligibility criteria will be listed at the close of the study.","FEMALE","22 Years","70 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.",[28],"Chronic Pelvic Pain Syndrome",[30],"Women","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-01-27",{"date":39,"type":22},"2028-12-01",{"name":41,"class":42},"Corewell Health East","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100524333","evaluating-the-role-of-the-guidewire-in-peripheral-intravenous-access-a-randomized-controlled-trial-of-ultrasound-guided-catheter-survival-100524333","NCT06107361","Evaluating the Role of the Guidewire in Peripheral Intravenous Access: A Randomized Controlled Trial of Ultrasound-Guided Catheter Survival","Study Participants Inclusion Criteria:\n\n≥ than 18 years old Vascular Access Score of 4 or 5\n\nVascular Access Score:\n\n1. Visible with distention and easily palpable\n2. Visible and easily palpable\n3. Not visible and easily palpable\n4. Visible and poorly palpable\n5. Not visible and poorly or non-palpable\n\nStudy participants exclusion criteria:\n\n\\\u003C18 years old Restricted mobility of elbow joint Cognitively impaired. Skin complications that limit access to the potential IV site\n\nClinician Participants Inclusion Criteria:\n\nClinician working in the emergency department at Corewell Health William Beaumont University Hospital (physician, advanced practice provider, nurse, technician) Competency in Operation STICK, which is an vascular access training program.\n\nClinician participants exclusion criteria:\n\nNone","ALL","18 Years",{"count":53,"type":22},360,[25],"This is a prospective, parallel, non-blinded, two-arm randomized controlled trial of intravenous catheter failure evaluating the impact of a built-in guide wire. The objective of this study is to demonstrate that the control ultralong intravenous catheter (IV) without the guide wire is non-inferior to the experimental catheter with the guide wire. After obtaining consent, eligible patients will be randomly allocated to control Arm 1 (ultralong intravenous catheter) or experimental Arm 2 (ultralong intravenous catheter with guide wire) in a ratio of 1:1 via a computer-generated randomization schedule. The participants will be followed to collect data until the catheter is removed.",[57,58],"Peripheral Intravenous Vein Catheter Phlebitis","Intravenous Infection",[60,61,62,63,64,65],"PIV","BBraun Ultra Long Catheter","BD Accucath","Phlebitis","IV infection","peripheral intravenous","2026-06-09",{"date":68,"type":35},"2026-06-10",{"date":70,"type":35},"2023-11-07",{"date":72,"type":22},"2026-07-31",{"name":41,"class":42},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100561688","cardiac-radioablation-for-vt-100561688","NCT06593418","Cardiac Radioablation for VT","A Phase I\u002FII Study of Cardiac Radioablation for Refractory Ventricular Tachycardia","Inclusion Criteria:\n\n* Participants must be 18 years or older.\n* Automatic implanted cardiac defibrillator present.\n* VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.\n* Ejection fraction ≥20%.\n* At least one previous cardiac ablation for VT.\n* VT refractory despite antiarrhythmic medications.\n* Likely to live for 12 months in the absence of VT.\n* AICD in a position in the chest RT to be given without direct radiation.\n* Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.\n* The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.\n\nExclusion Criteria:\n\n* Class IV heart failure\n* Abandoned leads.\n* Prior radiation therapy to the chest or upper abdomen.\n* Interstitial lung disease.",{"count":82,"type":22},24,[25],"The goal of this interventional study is to determine the minimum dose necessary for successful cardiac radioablation of refractory ventricular tachycardia (VT) and to study the utility of target volume definition using Delayed Enhancement Cardiac MRI (DE-CMR) .",[86,87],"Ventricular Tachycardia","Myocardial Infarction","NOT_YET_RECRUITING","2026-04-15",{"date":91,"type":35},"2026-04-20",{"date":93,"type":22},"2026-07",{"date":95,"type":22},"2028-01",{"name":41,"class":42},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100493354","quantitative-mri-assessment-of-breast-cancer-therapy-response-100493354","NCT05704062","Quantitative MRI Assessment of Breast Cancer Therapy Response","Functional Magnetic Resonance Imaging Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Patients with histologically confirmed breast cancer who are scheduled to receive standard of care neoadjuvant chemotherapy prior to surgical management\n* No contraindication for an MRI exam\n* Normal kidney functional for receiving a standard dose of gadolinium-based MRI contrast agent through IV injection\n* Not pregnant\n* Ability to understand and the willingness to sign a written informed consent document. A signed study-specific informed consent must be obtained prior to any study specific procedures\n\nExclusion Criteria:\n\n* Patients who would be normally excluded from undergoing an MRI examination - patients with a pacemaker, aneurysm clip, or any other condition that would warrant avoidance of a strong magnetic field\n* Patients who are unable to cooperate for an MRI exam lasting about 45 min, and\u002For have known allergic reaction to gadolinium-based contrast agent\n* Severe claustrophobia precluding subject from undergoing MRI\n* Patients with acute or chronic kidney dysfunction (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 60 ml\u002Fmin\u002F1.73 m\\^2 as calculated using the Modification of Diet in Renal Disease \\[MDRD\\] equation)\n* Pregnant participants are excluded from this study because it is difficult for them to lie prone on the MRI table and because of possible risk to the fetus\n* Cognitively impaired",{"count":105,"type":22},135,"OBSERVATIONAL","The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \\& Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very strong magnet and no radiation to take very detailed pictures of parts of the body. MRI is often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment in order to measure the tumor size changes in response to treatment, and in order to plan for surgery. MRI is used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment. Tumor size change usually happens late during the period of treatment, and tumor size measured with MRI after treatment can overestimate or underestimate the residual cancer. This makes it difficult to do the right surgical planning. In addition to measuring tumor size, the MRI scans in this research study will also measure changes in tumor blood vessels and the number of cancer cells per unit of tumor volume. The purpose of this study is to see whether MRI measurements of these functional tumor properties provide better early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy than tumor size measurement. This is an observational study because the MRI procedures are not expected to have an effect on health outcomes. Eligible participants on this study are receiving standard of care neoadjuvant treatment for their cancer.",[109],"Breast Cancer","2026-04-14",{"date":112,"type":35},"2026-04-17",{"date":114,"type":35},"2010-03-18",{"date":116,"type":22},"2027-05-31",{"name":41,"class":42},4,{"id":120,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":26,"conditions":123,"keywords":124,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":43},"100527656",{"count":21,"type":22},[25],[28],[30],"2025-12-05",{"date":127,"type":35},"2025-12-11",{"date":129,"type":35},"2025-06-30",{"date":39,"type":22},{"name":41,"class":42},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100508449","effect-of-peri-urethral-stimulation-on-intra-urethral-pressure-100508449","NCT05900570","Effect of Peri-Urethral Stimulation on Intra-Urethral Pressure","The Effect of Acute Peri-Urethral Neurostimulation on Intra-Urethral Pressure In Women With Stress Urinary Incontinence (SUI) - Urodynamic Early Feasibility Study","Inclusion Criteria:\n\n* Female aged 18 years old or older\n* Capable of understanding the clinical study procedures and giving informed consent\n* Willing and able to undergo the study procedure\n* Diagnosis of SUI or stress predominant mixed incontinence, for at least 6 months\n* Provided authorization to use and disclose information for research purposes\n\nExclusion Criteria:\n\n* Predominant urge incontinence per patient report or medical record\n* Active symptomatic uncontrolled bladder instability as determined by the investigator\n* Regularly or intermittently used a urethral catheter\n* Active bladder cancer (currently undergoing or scheduled to undergo treatment for bladder cancer).\n* Previous radiation treatment in the pelvic floor\n* History or symptoms of cystocele, enterocele or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator\n* Current infection (urethritis, cystitis or vaginitis) as determined by investigator.\n* Active herpes genitalis\n* Unevaluated hematuria\n* Currently taking, or has taken within 4 weeks prior to the screening\u002Fbaseline visit, pharmacological treatment for SUI (including but not limited to, alpha adrenergics, and tricyclic antidepressants)\n* Severe or uncontrolled diabetes, (defined as being a diabetic with a hemoglobin A1c of ≥10%) per patient medical record.\n* History of drug\u002Falcohol abuse, mental dysfunction, or other factors limiting her ability to cooperate fully\n* Pregnancy test with positive result during screening or women who are breastfeeding\n* Women who are pregnant and\u002For have given birth in the previous 12 months\n* Have implanted active neurostimulators, pacemakers, or defibrillators; neurostimulators which are passive or that can be briefly turned off for the stimulation procedure are acceptable\n* Known systemic neurological dysfunctions\n* Severe coagulation disorders\n* Medically unstable at time of study and unsafe to undergo urodynamic testing (UDT) as determined by the investigator\n* Presence of an artificial urinary sphincter\n* Any medical condition (e.g. Multiple Sclerosis, spinal cord injury, mobility) or uncontrolled chronic disease (e.g. renal diseases that requires dialysis) that would interfere with the patient's ability to comply with the protocol and\u002For may affect the outcome of this study or safety of the subject as determined by the investigator",{"count":140,"type":22},20,[25],"The purpose of this early feasibility prospective study is to gain initial understanding of the effect of acute peri-urethral neurostimulation on the perineal nerves on intra-urethral pressure.",[144],"Stress Urinary Incontinence",{"date":127,"type":35},{"date":147,"type":35},"2024-02-26",{"date":149,"type":22},"2027-01",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":159,"minAge":51,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":43},"100467736","emsella-chair-vs-sham-for-male-sexual-dysfunction-100467736","NCT05370651","Emsella Chair vs Sham for Male Sexual Dysfunction","A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Male Sexual Dysfunction","Emsella_EJD","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about adverse events and other clinically important information.\n2. Men ≥ 18 years of age.\n3. Sexually active within the past 12 weeks and plan to be sexually active during the next 12 weeks.\n\n5\\. Self-reported ejaculatory dysfunction symptoms present \\>3 months 6. Self-reported failed conservative care of behavioral modifications and\u002For oral medications.\n\n7\\. Subject agrees not to start any new treatment for erectile dysfunction or ejaculatory dysfunction during the treatment and follow-up periods.\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds, due to weight limits of the Emsella Chair.\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, thigh, or buttocks.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Previous or current penile prosthesis.\n7. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n8. Active urethral diverticula\n9. Known history of urethral stricture disease\n10. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has sexual dysfunction of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n14. Current use of neuromodulation therapy, including Interstim and percutaneous tibial nerve stimulation (PTNS), for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.","MALE",{"count":161,"type":22},117,[25],"We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham controlled, randomized blinded study. Participants in phase 2 will be randomized to receive either active treatment or sham. Potentially a total of 117 participants for both phases will be enrolled.\n\nThe purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of sexual dysfunction, specifically erectile dysfunction (EjD) in men.",[165,166],"Male Sexual Dysfunction","Ejaculatory Dysfunction",[165],{"date":127,"type":35},{"date":170,"type":35},"2022-12-14",{"date":172,"type":22},"2027-12",{"name":41,"class":42},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":43},"100429512","btl-emsella-chair-versus-sham-for-the-treatment-of-overactive-bladder-100429512","NCT04873037","BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder","A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Overactive Bladder","EmsellaOAB","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about AEs and other clinically important information.\n2. Women and men ≥ 18 years of age\n3. Self-reported bladder symptoms present ≥ 3 months\n4. Self-reported failed conservative care of behavioral modifications and\u002For oral medications\n5. On a stable dose of antimuscarinics\u002Fbeta-3 agonists for ≥ 4 weeks, and willing to remain on the medication for the duration of the study OR discontinued antimuscarinics\u002Fbeta-3 agonists for ≥ 2 weeks\n6. Ambulatory and able to use a toilet independently, without difficulty\n7. Subject agrees not to start any new treatment for OAB (medication or otherwise) during the treatment and follow-up periods.\n\n   For Females Only:\n8. If of child-bearing age and female, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, IUD, implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, buttocks, and thighs, at the discretion of the investigator.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, copper intrauterine devices, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n7. Active urethral diverticula\n8. Known vesicoureteral reflux\n9. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n10. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation. Skin cancers are permitted.\n11. Subject has used the BTL EMSELLA device previously\n12. Subject has urinary incontinence of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n13. Current urinary tract infection. If a subject has a confirmed symptomatic UTI at screening, per investigator's clinical judgment, they will be deferred from screening until treatment is completed, and may resume once symptoms have resolved\n14. Current use of neuromodulation therapy, including interstim and PTNS, for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    For Females Only:\n17. Pregnant, or planning to become pregnant, at screening or anytime throughout the study period\n\n    * Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.",{"count":183,"type":22},166,[25],"The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.",[187,188,189,190],"Overactive Bladder Syndrome","Overactive Bladder","Urinary Frequency","Urinary Urgency",[188],{"date":127,"type":35},{"date":194,"type":35},"2021-11-22",{"date":196,"type":22},"2028-12",{"name":41,"class":42},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":43},"100372766","btl-emsella-chair-versus-sham-for-the-treatment-of-stress-urinary-incontinence-100372766","NCT04133675","BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence","A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Stress Urinary Incontinence","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about AEs and other clinically important information.\n2. Females and males, 18 to 80 years of age, inclusive, at screening\n3. Positive Cough or Bladder Stress Test at screening\n4. Subject agrees not to start any new treatment (medication or otherwise) during the treatment and follow-up periods.\n\n6\\. Subject agrees to maintain a stable dose of any medication known to affect lower urinary tract function, including but not limited to anticholinergics, tricyclic antidepressants, beta-3 adrenergic agonist, or α-adrenergic blockers, throughout the treatment and follow-up periods.\n\nFor Females Only:\n\n* Subject agrees to discontinue use of bladder support devices, including but not limited to vaginal pessary, during the screening, treatment, and follow-up periods.\n* If of child-bearing age and female, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, IUD, implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))\n\nFor Males Only:\n\n\\- Subject must be ≥ 4 months post radical prostatectomy\n\nExclusion Criteria:\n\n1. Pelvic floor physical therapy, including muscle training and\u002For electrostimulation, in a clinical setting within 30 days prior to screening\n2. Subject is morbidly obese (defined as body mass index 40 or greater)\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure or tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, buttocks, and lower extremities\n5. Implanted cardiac pacemaker or metal in the body, including, but not limited to drug pumps, neurostimulators, electronic implants, copper intrauterine devices (IUDs), and\u002For defibrillators\n6. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n7. Active urethral diverticula\n8. Known vesicoureteral reflux\n9. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n10. Treatment with urethral bulking agents within the 6 months prior to the Screening Visit\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has urinary incontinence of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy etc.\n14. Clinically confirmed urinary tract infection, requiring treatment as determined by the investigator, at the Screening Visit\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    For Females Only:\n17. Pregnant, or planning to become pregnant, at screening or anytime throughout the study period\n18. History of surgery with insertion of vaginal mesh for SUI\n19. Vaginal prolapse beyond the introitus\n20. Vaginal rejuvenation treatment, including laser treatments and radiofrequency therapy, within the 6 months prior to the Screening Visit\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.","80 Years",{"count":207,"type":22},110,[25],"Stress urinary incontinence (SUI) is a condition that affects both men and women. SUI is the involuntary leakage of urine caused by an increase in intra-abdominal pressure from activities such as exercise, coughing, laughing, or sneezing. It can significantly affect quality of life as patients avoid activities or behaviors that cause leakage. This clinical trial will compare the efficacy of the Emsella chair to sham and determine if electromagnetic technology is effective in the treatment of SUI.",[144],[212,213],"urinary incontinence","urine leakage",{"date":127,"type":35},{"date":216,"type":35},"2019-12-18",{"date":196,"type":22},{"name":41,"class":42},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":230,"conditions":231,"keywords":235,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":43},"100573369","phase-4-magnesium-and-cramping-100573369","NCT06745388","Magnesium and Cramping","Evaluating the Impacts of Intravenous Magnesium Sulfate and Ketamine on Cramping Pain and Total Opioid Consumption Following Hysteroscopy: A Prospective, Randomized Trial","Inclusion Criteria:\n\n* Patients undergoing an elective hysteroscopy or dilation and curettage (D\\&C)\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Chronic Pain Patients (taking opioids within one week of procedure)\n* Psychiatric Disorders (current treatment for anxiety\u002Fdepression)\n* Allergies to any of the medications that will be administered\n* Current use of magnesium, analgesics, antidepressants, anxiolytics, or opioids\n* ASA Physical Status 4 or above\n* Developmentally delayed patients that would not be able to verbalize pain scores\n* Minors (under 18 years of age)\n* Pregnant women",{"count":227,"type":22},150,[229],"PHASE4","Hysteroscopy (an exam to look inside the uterus) is one of the most frequently performed procedures for patients with cervical or uterine disorders. It is the gold standard for evaluating various intrauterine problems, pre-menopausal and post-menopausal abnormal uterine bleeding, as well as being a vital examination modality for infertility work-up. Although hysteroscopy is a minimally invasive procedure, it is still known to be a painful experience that requires effective analgesia (meaning pain reduction) to achieve maximum patient comfort and cooperation. Historically, opioids, particularly fentanyl, have held precedence as the primary agents for providing analgesia following surgery of this type. However, despite their efficacy, these agents come with notable drawbacks, including the potential for serious side effects such as respiratory depression, addiction, and postoperative nausea and vomiting.\n\nBoth magnesium and ketamine are routinely used to reduce pain following this procedure. Both drugs work on the N-methyl-D-aspartate (NMDA) receptor in the brain to reduce pain, and magnesium has an additional effect in that it can relax smooth muscles. Magnesium has been used successfully to reduce the pain associated with menstrual cramps, which is similar to the pain patients experience after hysteroscopy.\n\nA recent study demonstrated the benefits of adding intravenous magnesium with routine anesthesia during hysteroscopy, revealing a significant decrease in postoperative pain and rescue analgesics. However, this study did not compare the effects of magnesium to ketamine, nor did they characterize the nature of the patients' pain. It is unclear if the pain reduction with magnesium comes from its effect on the NMDA receptor or from it's cramp-reduction effect. We seek to establish whether administering IV magnesium, compared to ketamine, can specifically mitigate uterine cramping pain and total opioid consumption in hopes of finding additional safe and effective pain modalities for patients.\n\nThis is a prospective, randomized trial enrolling participants undergoing an elective hysteroscopy or Dilation and Curettage (D\\&C) at Corewell Health William Beaumont University Hospital in Royal Oak. Participants will be randomized to 1 of 3 treatments: Intravenous (IV) Magnesium, IV Push Ketamine, or Placebo. Opioid consumption is recorded via the electronic medical record (EMR), while overall pain and cramping pain will be captured post-procedure in the hospital and 24 hours later via a phone call.",[232,233,234],"Uterine Cramps","Postoperative Pain Management","Hysteroscopy",[236,237,238,239],"hysteroscopy","magnesium sulfate","cramping","ketamine","2025-08-15",{"date":242,"type":35},"2025-08-20",{"date":244,"type":35},"2025-07-29",{"date":246,"type":22},"2026-09",{"name":41,"class":42},""]